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To assess whether myocardial dysfunction after acute reperfusion ('stunning') may show delayed recovery, 33 patients of
the European Cooperative Study (rtPA vs placebo) had radionuclide angiocardiography on day 9 and after 3-6 months.
Sixteen patients (13 inferior, three anterior infarcts) had a normal left ventricular ejection fraction (LVEF) which
remained unchanged (55-4 vs 53-9%). In contrast, LVEF of 17 patients (10 inferior, seven anterior infarcts) with
depressed values on day 9 improved during follow-up from 38-8 to 45-2% /P<0-01). Improvement was only observed in
patients with early reperfusion defined a priori as peak creatine kinase value" •< 15 h of pain onset (from 409 to 49-3%;
P<0-05) in contrast to patients without reperfusion (from 34-0 to 35-2%; ns). Accordingly, LVEF increased in patients
with open infarct-related arteries at hospital discharge (n = 8; P = 0-053) but not with persistent occlusion (n = 7;
P = 0-ll). Thus, a depressed LVEF observed 9 days after reperfusion may show delayed recovery due to prolonged
stunning. Therefore, after thrombolysis, left ventricular function may not be evaluated definitively at hospital discharge;
results of such studies should be interpreted with caution.
Introduction
Most large prospective studies of thrombolysis in acute
myoardial infarction have shown a significant reduction
in infarct size and improvement in survival vs standard
treatment'1"*1, however, left ventricular (LV) function has
been improved only marginally by this treatment'6"91. One
reason for this apparent disparity of treatment effects may
be slow recovery of post-ischaemic LV dysfunction. In
clinical studies, LV function was usually assessed within
the first few days after the acute infarct, before hospital
discharge; however, experimental studies indicated that
depending on the duration of the acute occlusion, full
recovery of LV function may take several weeks'10"1. Since
left ventricular ejection fraction (LVEF) remains fairly
constant in patients after myocardial infarction without
thrombolysis1121, the aim of this study was to determine
whether there would be an improvement in LVEF after
hospital discharge in patients with early reperfusion,
compared with those without reperfusion.
Methods
Since this study represents a substudy of the multicentre
European Cooperative Study comparing the effects of
recombinant tissue-type plasminogen activator (rtPA) vs
placebo on LV function, the methods were identical to
those reported earlier161. In short, patients below 71 years
of age with acute chest pain lasting more than 30 min and
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significant ST-elevation in more than one lead who could
be treated within 5 h of pain onset were randomized to
100 mg of rtPA or placebo, each combined with heparin
and aspirin. Coronary and LV angiograms were only per-
formed before hospital discharge, i.e. in our hospital on
the 10th day after the acute event.
In addition to the general protocol, our patients under-
went creatine kinase (CK) determinations every 4 h dur-
ing the initial 24 h to detect early reperfusion, defined a
priori for this study as time to peak CK of < 15 h; in
addition radionuclide angiocardiograms were performed
at rest 1 day prior to the contrast ventriculogram and 3
months later, after withdrawal of all cardiac medication
for at least 24 h. The 317 CK values determined at our
hospital as well as in the central laboratory of the
European Cooperative Study in Maastricht'61 showed
excellent agreement: y = - 7-1 + 2-9x, r = 0-92, /> < 00001.
LVEF determinations by our radionuclide technique and
by the centrally analysed contrast ventriculograms
showed also a significant correlation (y = 29-3+0-5x,
r = 0-7, /><00001), despite the fact that they were
measured on different days and with different laboratory
conditions. We have previously shown that the radio-
nuclide LVEF values are valid and reproducible with
a variability of 2 standard deviations (95%) of
<5EF%'1314'.
PATIENTS
Included in this study were all 33 patients from our
hospital, participating in the European Cooperative
Study, who survived the acute event and follow-up and
who had both early and follow-up radionuclide studies.
There were 27 men and six women, with a mean age of
53-9 years (27-70 years). Ten patients had an anterior
and 23 an inferior infarct, 18 had received rtPA and 15
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Table I Patients
LVEF day 9 £50% <50%
mean age (years)
sex (male/female)
inferior/anterior infarct (n)
1-/2-/3-vessel disease (n)
rtPA/placebo (n)
PTCA/CABG (n)
16
53-4
14/2
13/3
9/6/1
6/10
17
54-4
13/4
10/7
11/4/1
12/5
7
LVEF = left ventricular ejection fraction, rtPA = recombinant tissue
plasminogen activator, PTCA = percutaneous transluminal angio-
plasty, CABG = coronary artery bypass grafting.
placebo. Coronary angiography after 10 days showed
one-vessel disease in 20, two-vessel disease in 10 and three-
vessel disease in two patients. Between early and follow-
up studies, 15 patients had PTCA or CABG surgery.
Patients were divided into two groups according to their
initial radionuclide LVEF: 16 patients had a normal
LVEF ;>50%, as defined previously'13'; in this group no
significant change was expected with time; 17 patients had
an abnormal value of <50% (Table 1). There were no
significant differences between the two groups, although
more patients with a depressed LVEF had received rtPA.
Statistics
All values are given as mean± 1 SEM. Groups were
compared by Student's Mest for unpaired samples or the
Chi square test, where appropriate, and values within one
group were compared by Student's /-test for paired
samples. P values <0-05 were considered statistically sig-
nificant, <010 as ofborderline significance and >0-10as
non-significant.
Results
Changes in LV function between early and follow-up
studies for patients with initially normal and abnormal
LVEF values are shown in Fig. 1. In patients with an
LVEF of ^50%, values remained fairly constant over
time, whereas they increased significantly in patients with
a depressed value on day 9. This increase was markedly
higher than the spontaneous variability of this
measurement with time114'.
In order to define factors responsible for this improve-
ment in LVEF over time, patients with an initial value of
< 50% were subdivided by time to peak CK (as a marker
of early reperfusion) and drug treatment given (Fig. 2).
There was a significant improvement only in patients with
enzymatic signs of early reperfusion. Similarly, only
patients who received rtPA showed a signficant late
improvement of LVEF (from 37-8 + 3-2 to 46-5 + 4-6%,
P < 001; only one patient in each subgroup of Fig. 2 had
to be exchanged).
When patients were subdivided by vessel patency
according to the 10 day coronary angiogram, improve-
ment of LVEF over time was only of borderline signifi-
cance for eight patients with an open infarct-related artery
(from 38-9 ±4-5 to 441 ± 5-5%; P = 0-053). There was no
significant change for seven patients with subtotal/total
occlusions before hospital discharge (P = 011). LVEF
tended to improve over time in both anterior and inferior
infarcts, but the changes were not significant if analysed as
two separate sub-groups.
Discussion
This small substudy of the European Cooperative
Study, comparing the effects of rtPA and placebo on LV
function, makes an important observation: the possibility
of delayed recovery of LV function even after hospital
discharge. This is not surprising in view of experimental
evidence that reperfusion after <2 h of coronary occulsion
in dogs resulted in salvage of jeopardized myocardium
with gradual improvement of function of salvaged tissue
requiring 3 weeks or more1'01. Other studies suggested
there may be even later but little recovery of function
with occlusion of 3 h followed by reperfusion'1''. Investi-
gations of the ultrastructure of this so-called 'stunned'
myocardium'161 indicated that reperfused, salvaged myo-
cardium not only has functional and biochemical but also
ultrastructural abnormalities and that the latter may per-
sist even after there has been recovery of high energy phos-
phate stores and of function'101. Similar observations of
prolonged stunning and delayed recovery have been
reported after emergency PTCA in cardiogenic shock
patients'171 and, most recently, after thrombolysis and
documented reperfusion'181, similarly to the present
results. The latter contrast ventriculographic study also
looked at regional function and showed that late improve-
ment of global function was due to an increased motion of
the infarct region'"1. Similarly to the present observations,
improvement was mainly seen in large infarcts, i.e. in
patients with a depressed LVEF and not in those with a
normal function shortly after the acute event. Those two
papers"8191, however, either described survival in relation
to LV function or regional function but did not stress the
clinical relevance of late recovery of LV function.
For this study, time to peak CK was defined a priori as
a marker of early reperfusion since all other clinical
parameters of reperfusion are even less reliable1201.
Unfortunately, no acute angiograms were performed as in
the study by Schmidt el a/.'181 where, again, late recovery
of LV function was only found in patients with docu-
mented reperfusion. The 10 day angiogram in the present
study also showed a difference in the extent of late recov-
ery between patients with open vs those with subtotally or
totally occluded infarct-related arteries. However, these
angiographic findings reflect a 10-day vessel status and
not early reperfusion since in the meantime spontaneous
late (after hours or days) reperfusion and also silent
reocclusion might have occurred in some patients, as
observed in the European Cooperative Study161. Late
recovery of function was mainly seen in patients treated
with rtPA, which has been shown to increase early reper-
fusion significantly in comparison with placebo122"241.
Finally, revascularization procedures were performed
overall in similar percentages in patients with (10/20)
216 M. Pfisterer et al.
EF =5 30% EF <50%
10
Ooy 9 Follow-up Day 9 Follow-up
Figure I Change in left ventricular ejection fraction (LVEF) over time. Note the significant improvement in LVEF in
patients with an initial LVEF < 50% in contrast to no change in patients with a value of ^50%. n = 33. • • rtPA,
O O placebo.
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Figure 2 Effect of early reperfusion assessed by time to peak maximal creatine kinase (CICmax) ^ 15 h on the change of LVEF
over time. Note the significant improvement in patients with signs of reperfusion vs no change in patients without reperfusion.
n = 17 with initial EF < 50%, • • rtPA, O O placebo.
and without (4/13; ns) signs of early reperfusion and have
previously been shown not to change resting LVEF
significantly1211.
Although the sample size of this substudy may be too
small to allow definite conclusions, the observations are in
accordance with those of Schmidt et a/.|18) as well as with
experimental evidence of delayed functional recovery
over weeks; they seem to imply that after acute myo-
cardial infarction and thrombolysis LV function may
not be definitely evaluated at hospital discharge. Studies
analysing LV function within the first few days after acute
myocardial infarction and thrombolysis should therefore
be interpreted with caution. Thus, prolonged stunning
might be one reason for the disparity between the effects
of thrombolysis on infarct size and survival vs the lack of
improvement in LV function reported in the literature.
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